SG Americas Securities LLC Invests $134,000 in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

SG Americas Securities LLC acquired a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) in the fourth quarter, HoldingsChannel reports. The firm acquired 12,289 shares of the biopharmaceutical company’s stock, valued at approximately $134,000.

Several other hedge funds have also added to or reduced their stakes in MRNS. FMR LLC raised its stake in shares of Marinus Pharmaceuticals by 1,887.9% during the first quarter. FMR LLC now owns 4,433 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 4,210 shares during the last quarter. BluePath Capital Management LLC acquired a new stake in Marinus Pharmaceuticals in the third quarter valued at $38,000. Quantbot Technologies LP bought a new position in Marinus Pharmaceuticals during the 1st quarter worth $40,000. Ameritas Investment Partners Inc. acquired a new position in Marinus Pharmaceuticals during the 2nd quarter worth about $45,000. Finally, Jane Street Group LLC bought a new stake in shares of Marinus Pharmaceuticals in the 4th quarter valued at about $47,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on MRNS shares. Oppenheimer restated a “market perform” rating and set a $9.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. Robert W. Baird restated a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 price objective on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. Royal Bank of Canada reissued a “sector perform” rating and set a $3.00 target price (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday. Finally, StockNews.com cut shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $18.21.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS stock opened at $1.44 on Thursday. The firm has a 50 day moving average of $8.72 and a 200-day moving average of $8.45. The company has a market cap of $79.10 million, a price-to-earnings ratio of -0.55 and a beta of 0.91. The company has a quick ratio of 4.01, a current ratio of 4.07 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals, Inc. has a 52 week low of $1.11 and a 52 week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The company had revenue of $7.19 million during the quarter, compared to analyst estimates of $7.78 million. During the same quarter in the previous year, the business posted ($0.76) earnings per share. On average, equities analysts forecast that Marinus Pharmaceuticals, Inc. will post -2.43 earnings per share for the current year.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.